Prognosis
China’s Sinopharm Publishes Awaited Covid Vaccine Study Details
- Medical journal provides first detailed look at a Chinese shot
- China’s vaccines have been criticized for lack of transparency
This article is for subscribers only.
Vaccines from China’s Sinopharm successfully contained Covid-19, according to a study published in a prestigious U.S. medical journal, the first time detailed findings from a late-stage trial of a Chinese shot have appeared in the scientific literature.
The two inactivated vaccines developed by Sinopharm’s vaccine-making unit China National Biotec Group Co. prevented symptomatic infections by 72.8% and 78.1%, largely in-line with what the state-owned drugmaker previously announced. The findings were reported in the May 26 Journal of the American Medical Association.